Literature DB >> 6140379

Anaphylactic reaction to intravenous cyclosporin.

B D Kahan, C A Wideman, S Flechner, C T Van Buren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6140379     DOI： 10.1016/s0140-6736(84)90219-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 3.  Complications of cyclosporin therapy.

Authors:  B D Kahan; S M Flechner; M I Lorber; C Jensen; D Golden; C T Van Buren
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

4.  Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity.

Authors:  W S Bartynski; Z Zeigler; M P Spearman; L Lin; R K Shadduck; J Lister
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

5.  Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

6.  Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine.

Authors:  S A Gruber; S Venkataram; D M Canafax; R J Cipolle; L Bowers; D Elsberry; M McGuiggan; P E Hynes; J A Ritz; F H Gould
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

7.  Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia.

Authors:  Axel Forsse; Troels Halfeld Nielsen; Kevin Heebøll Nygaard; Carl-Henrik Nordström; Jan Bert Gramsbergen; Frantz Rom Poulsen
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

8.  Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.

Authors:  Karl Henrik Johannes Ehinger; Magnus Joakim Hansson; Fredrik Sjövall; Eskil Elmér
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

9.  Well-tolerated oral cyclosporine in a case of hypersensitivity to parenteral cyclosporine in postallogeneic bone marrow transplantation.

Authors:  Mahsa Moeinian; Hamed Sotoude; Zahra Mohebbi; Ali Asadollahi-Amin; Rambod Mozafari
Journal:  Indian J Pharmacol       Date:  2018 Mar-Apr       Impact factor: 1.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.